Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?
Aaron K Wong, Sara Vogrin, Pal Klepstad, Justin Rubio, Brian Le, Jennifer Philip, Andrew A Somogyi · 2024
Read Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer? by Aaron K Wong, Sara Vogrin, Pal Klepstad, Justin Rubio, Brian Le, Jennifer Philip, Andrew A Somogyi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11703413.txt.
Description
Aaron Wong and a team of co-authors asked if genes change how a pain drug works in cancer. Their study, from twenty twenty-four, looked at oxycodone use in people with pain from advanced cancer. Two genes shape how the body breaks down this drug. The team checked dose, blood levels, pain scores, and side effects by gene type.
The study ran at many centers and drew data from visits, forms, and blood tests. In the small group of thirty-three people, gene type did not split drug response. Higher blood levels of a drug by-product went with worse pain control. Readers learn that gene tests may not guide this drug's dose in cancer care.
Catalog record
| CREATOR | Aaron K Wong, Sara Vogrin, Pal Klepstad, Justin Rubio, Brian Le, Jennifer Philip, Andrew A Somogyi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |